KR102426541B1 - 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템 - Google Patents

과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템 Download PDF

Info

Publication number
KR102426541B1
KR102426541B1 KR1020177011301A KR20177011301A KR102426541B1 KR 102426541 B1 KR102426541 B1 KR 102426541B1 KR 1020177011301 A KR1020177011301 A KR 1020177011301A KR 20177011301 A KR20177011301 A KR 20177011301A KR 102426541 B1 KR102426541 B1 KR 102426541B1
Authority
KR
South Korea
Prior art keywords
ibs
antibody
vinculin
cdtb
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177011301A
Other languages
English (en)
Korean (ko)
Other versions
KR20170067795A (ko
Inventor
마크 피멘텔
크리스토퍼 창
Original Assignee
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세다르스-신나이 메디칼 센터 filed Critical 세다르스-신나이 메디칼 센터
Publication of KR20170067795A publication Critical patent/KR20170067795A/ko
Application granted granted Critical
Publication of KR102426541B1 publication Critical patent/KR102426541B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177011301A 2014-10-09 2015-10-08 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템 Active KR102426541B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462061877P 2014-10-09 2014-10-09
US62/061,877 2014-10-09
US201462085825P 2014-12-01 2014-12-01
US62/085,825 2014-12-01
PCT/US2015/054655 WO2016057772A1 (en) 2014-10-09 2015-10-08 Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Publications (2)

Publication Number Publication Date
KR20170067795A KR20170067795A (ko) 2017-06-16
KR102426541B1 true KR102426541B1 (ko) 2022-07-29

Family

ID=55653760

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177011301A Active KR102426541B1 (ko) 2014-10-09 2015-10-08 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템

Country Status (16)

Country Link
US (2) US10132814B2 (cg-RX-API-DMAC7.html)
EP (1) EP3204771B1 (cg-RX-API-DMAC7.html)
JP (1) JP6784669B2 (cg-RX-API-DMAC7.html)
KR (1) KR102426541B1 (cg-RX-API-DMAC7.html)
CN (1) CN107003308B (cg-RX-API-DMAC7.html)
AU (1) AU2015330872B2 (cg-RX-API-DMAC7.html)
CA (1) CA2962493C (cg-RX-API-DMAC7.html)
ES (1) ES3028294T3 (cg-RX-API-DMAC7.html)
IL (1) IL251606B (cg-RX-API-DMAC7.html)
MX (1) MX384921B (cg-RX-API-DMAC7.html)
NZ (1) NZ730490A (cg-RX-API-DMAC7.html)
PL (1) PL3204771T3 (cg-RX-API-DMAC7.html)
PT (1) PT3204771T (cg-RX-API-DMAC7.html)
RU (1) RU2706361C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201702395WA (cg-RX-API-DMAC7.html)
WO (1) WO2016057772A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396652B1 (en) 2009-02-11 2017-12-13 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin
EP2895856B1 (en) 2012-09-17 2017-10-04 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
KR102259588B1 (ko) 2013-10-09 2021-06-02 세다르스-신나이 메디칼 센터 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료
NZ730490A (en) 2014-10-09 2021-07-30 Cedars Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
CN113447649B (zh) * 2021-07-01 2022-04-19 浙江大学 一种检测抗粘着斑蛋白-IgG抗体的试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506144A (ja) 2006-08-15 2010-02-25 プロメテウス ラボラトリーズ インコーポレイテッド 過敏性腸症候群診断方法
JP2011507509A (ja) 2007-12-20 2011-03-10 インデックス・ダイアグノスティックス・エイビイ Ｉｂｄとｉｂｓとの区別、ｉｂｄの疾患タイプ間の更なる識別における使用する方法およびキット
US20120003158A1 (en) 2008-10-13 2012-01-05 Danny Alexander Biomarkers for Inflammatory Bowel Disease and Methods Using the Same
WO2014042828A2 (en) * 2012-09-17 2014-03-20 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
WO2003097854A2 (en) 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
WO2004024097A2 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
EP1664796B1 (en) 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate ankylosing spondylitis
KR101202934B1 (ko) 2003-12-05 2012-11-19 후소 야쿠힝 고교 가부시끼가이샤 세포팽창화 치사독 및 그것을 표적으로 한 캄필로박터속에 속하는 세균의 검출
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
KR101493125B1 (ko) 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
EP2396652B1 (en) 2009-02-11 2017-12-13 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin
WO2010093776A1 (en) 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
JP5477671B2 (ja) 2012-02-28 2014-04-23 三菱マテリアル株式会社 サーミスタ用金属窒化物材料及びその製造方法並びにフィルム型サーミスタセンサ
KR102259588B1 (ko) 2013-10-09 2021-06-02 세다르스-신나이 메디칼 센터 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료
NZ730490A (en) 2014-10-09 2021-07-30 Cedars Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
JP2020507755A (ja) 2017-01-30 2020-03-12 シーダーズ−サイナイ メディカル センター 強皮症の診断法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506144A (ja) 2006-08-15 2010-02-25 プロメテウス ラボラトリーズ インコーポレイテッド 過敏性腸症候群診断方法
JP2011507509A (ja) 2007-12-20 2011-03-10 インデックス・ダイアグノスティックス・エイビイ Ｉｂｄとｉｂｓとの区別、ｉｂｄの疾患タイプ間の更なる識別における使用する方法およびキット
US20120003158A1 (en) 2008-10-13 2012-01-05 Danny Alexander Biomarkers for Inflammatory Bowel Disease and Methods Using the Same
WO2014042828A2 (en) * 2012-09-17 2014-03-20 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Walter Morales et al., 'Antibodies to Cytolethal Distending Toxin B and Auto-Antibodies to Human Vinculin Are Elevated in IBS Subjects', Gastroenterology, 2013, Vol. 144, Abstract No. Tu2056. 1부.*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Also Published As

Publication number Publication date
IL251606A0 (en) 2017-06-29
US10132814B2 (en) 2018-11-20
NZ730490A (en) 2021-07-30
EP3204771A1 (en) 2017-08-16
KR20170067795A (ko) 2017-06-16
PT3204771T (pt) 2025-05-20
JP2017531801A (ja) 2017-10-26
JP6784669B2 (ja) 2020-11-11
EP3204771A4 (en) 2018-03-14
RU2017115663A3 (cg-RX-API-DMAC7.html) 2019-05-16
SG11201702395WA (en) 2017-04-27
AU2015330872A1 (en) 2017-04-13
US20160103136A1 (en) 2016-04-14
CN107003308B (zh) 2020-02-11
IL251606B (en) 2020-08-31
CA2962493C (en) 2023-01-10
MX2017004516A (es) 2017-10-12
RU2706361C2 (ru) 2019-11-18
ES3028294T3 (en) 2025-06-18
CN107003308A (zh) 2017-08-01
RU2017115663A (ru) 2018-11-13
CA2962493A1 (en) 2016-04-14
EP3204771B1 (en) 2025-03-12
WO2016057772A1 (en) 2016-04-14
MX384921B (es) 2025-03-14
PL3204771T3 (pl) 2025-07-28
US20190187153A1 (en) 2019-06-20
US10690679B2 (en) 2020-06-23
AU2015330872B2 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
KR102426541B1 (ko) 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템
KR102259588B1 (ko) 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료
EP2904395B1 (en) Antibodies to microbiome as diagnostic markers for ibs
KR102203568B1 (ko) 장 및 방광의 운동 장애 및 섬유근육통의 진단 및 치료
US12222352B2 (en) Diagnosis of scleroderma
US20240159772A1 (en) Methods for Detecting and Treating Irritable Bowel Syndrome
HK1234824B (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
HK1234824A1 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
HK1213050B (en) Antibodies to microbiome as diagnostic markers for ibs

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4